Press Release: Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Dow Jones11-09

On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27

Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206 received Fast Track designation from the FDA

Cash, cash equivalents and short-term investments of $169.7 million as of September 30, 2026, anticipated to fund operations into 2H 2028

MORRISTOWN, N.J., Nov. 9, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended September 30, 2026, and provided recent corporate highlights.

"We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027," said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics. "We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months. With its improved biparatopic design, HWK-206 has demonstrated enhanced preclinical antitumor activity compared to other SEZ6-targeted ADCs. Our global clinical development strategy is focused on efficiently evaluating how these preclinical attributes translate in patients with small-cell lung cancer."

Q3 2026 and Recent Operational Highlights:

   -- Continued to advance the ongoing Phase 1 trials of HWK-007 and HWK-016. 
 
          -- HWK-007, a PTK7-targeting ADC, is being evaluated in patients with 
             non-squamous, EGFR wild-type non-small cell lung cancer; 
             platinum-resistant ovarian cancer; and endometrial cancer 
             (NCT07444814). 
 
          -- HWK-016, a MUC16-targeting ADC, is being evaluated in patients 
             with advanced ovarian and endometrial cancers (NCT07470853). 
   -- Initiated the Phase 1 clinical trial of HWK-206 in the U.S. and received 
      Fast Track designation from the U.S. Food and Drug Administration (FDA). 
 
          -- HWK-206 is a novel, biparatopic, SEZ6-targeting ADC utilizing the 
             same TOP1i-linker payload as Whitehawk's first two programs. 
             HWK-206 is being developed initially for small-cell lung cancer 
             (SCLC) and other neuroendocrine tumors. 
 
          -- Whitehawk submitted an Investigational New Drug (IND) application 
             in China and anticipates activating its first clinical sites in 
             China in Q1 2027. 
 
          -- The study is designed to evaluate an accelerated sequence of 
             planned dose levels, starting at 3 mg/kg, informed by Whitehawk's 
             experience with HWK-007 and HWK-016. The initial dose-escalation 
             portion will focus on patients with SCLC, providing an opportunity 
             to evaluate HWK-206 against established clinical benchmarks. 
 
          -- Initial Phase 1 data from HWK-206 is expected by year-end 2027. 
   -- Presented real-world analyses supporting PTK7 as a durable ADC target in 
      EGFR wild-type NSCLC at World Conference on Lung Cancer 2026. PTK7 
      expression remained stable following standard-of-care therapies, 
      supporting its relevance as a target in second-line or later-line EGFR 
      wild-type NSCLC. 
   -- Presented real-world analyses supporting MUC16 as a durable ADC target in 
      ovarian cancer at International Gynecologic Cancer Society 2026. MUC16 
      expression remained high and stable following standard-of-care therapies, 
      supporting its potential utility in both combination approaches and 
      relapsed settings. High MUC16 expression was associated with poor 
      real-world overall survival in high-grade serous ovarian carcinoma, the 
      most common subtype of ovarian cancer. 
   -- Appointed Vijay Iyengar, MD, to Board of Directors. Dr. Iyengar, a former 
      Incyte executive, brings extensive oncology, corporate strategy, business 
      development and medical affairs experience to Whitehawk. 

Q3 2026 Financial Results:

   -- Cash, cash equivalents and short-term investments as of September 30, 
      2026, were $169.7 million as compared to $145.7 million as of December 
      31, 2025. Cash is anticipated to fund operations into 2H 2028 based on 
      current plans. 
   -- Research and development expenses were $18.1 million for the three months 
      ended September 30, 2026, as compared to $14.3 million for the three 
      months ended September 30, 2025. 
   -- Net loss for the three months ended September 30, 2026, was $21.2 million 
      as compared to $17.7 million for the three months ended September 30, 
      2025. 

Upcoming Investor Conferences:

   -- Jefferies Global Healthcare Conference in London -- management will 
      participate in investor meetings, and Dave Lennon will participate in a 
      fireside chat on November 16, 2026, at 9:30 AM GMT. 
   -- Piper Sandler 38th Annual Healthcare Conference -- management will 
      participate in investor meetings, and Dave Lennon will present a 
      corporate overview on December 2, 2026, at 1:30 PM ET. 
   -- A live webcast of the fireside chat and presentation can be accessed by 
      visiting the Whitehawk Therapeutics IR website and will be available for 
      replay for approximately 30 days following the events. 

About Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index.

More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the potential therapeutic value and market opportunity for the Company's ADC portfolio; plans related to the Company's development of its portfolio of ADC assets, including the anticipated timing of the initial Phase 1 data from clinical trials for HWK-007 and HWK-016 in 1H 2027 and for HWK-206 by year-end 2027, and the anticipated timing of activating our first clinical sites in China for the HWK-206 Phase 1 trial in Q1 2027; expectations regarding the beneficial characteristics, design features, safety, efficacy, therapeutic effects and the size of the potential targeted markets with respect to the Company's ADC assets; and the sufficiency of the Company's existing capital resources and the expected timeframe to fund the Company's future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of the ADC portfolio, including potential delays in the commencement, enrollment and completion of clinical trials; failure to demonstrate the efficacy of the ADC portfolio in preclinical and clinical studies; the risk that unforeseen adverse reactions or side effects may occur in the course of testing of the ADC assets; and risks related to the Company's estimates regarding future expenses, capital requirements and need for additional financing.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

IR@whitehawktx.com

 
                         WHITEHAWK THERAPEUTICS, INC. 
                    CONDENSED CONSOLIDATED BALANCE SHEETS 
                                (In thousands) 
                                 (Unaudited) 
 
                           September 30,                 December 31, 
                               2026                          2025 
                    ---------------------------  ----------------------------- 
Assets 
Current assets: 
   Cash and cash 
    equivalents       $                  68,973      $                  37,568 
   Short-term 
    investments                         100,699                        108,129 
   Prepaid 
    expenses and 
    other current 
    assets                                2,299                          3,316 
                    ---------------------------  ----------------------------- 
Total current 
 assets                                 171,971                        149,013 
Property and 
 equipment, net                               3                              3 
Operating lease 
right-of-use 
assets                                      212                             -- 
Other assets                              1,500                          1,814 
                                                 ----------------------------- 
Total assets            $               173,686        $               150,830 
                    ===========================  ============================= 
 
Liabilities and 
stockholders' 
equity 
Current 
liabilities: 
   Accounts 
    payable         $                     2,224  $                         917 
   Accrued 
    liabilities                           8,087                         13,602 
   Operating lease 
   liabilities, 
   current 
   portion                                  130                             -- 
                    --------------------------- 
Total current 
 liabilities                             10,441                         14,519 
                    ---------------------------  ----------------------------- 
   Operating lease 
   liabilities, 
   net of current 
   portion                                   88                             -- 
                    ---------------------------  ----------------------------- 
Total liabilities                        10,529                         14,519 
Stockholders' 
equity: 
   Common stock                               5                              4 
   Additional 
    paid-in 
    capital                             576,661                        489,437 
   Accumulated 
    other 
    comprehensive 
    (loss) income                         (216)                            120 
   Accumulated 
    deficit                           (413,293)                      (353,250) 
                    ---------------------------  ----------------------------- 
Total 
 stockholders' 
 equity                                 163,157                        136,311 
                    ---------------------------  ----------------------------- 
Total liabilities 
 and stockholders' 
 equity                 $               173,686        $               150,830 
 
 
                                         WHITEHAWK THERAPEUTICS, INC. 
                               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
                       (In thousands, except share data and earnings per share amounts) 
                                       (Unaudited) 
 
                                   Three months ended                           Nine months ended 
                                     September 30,                                September 30, 
                      --------------------------------------------  ------------------------------------------ 
                              2026                   2025                   2026                  2025 
                      ---------------------  ---------------------  ---------------------  ------------------- 
Revenue 
   Product sales, 
    net               $                   -  $                   -  $                   -    $           7,145 
Total Revenue                             -                      -                      -                7,145 
                      ---------------------  ---------------------  ---------------------  ------------------- 
Operating expenses 
   Selling, general 
    and 
    administrative                    4,805                  5,201                 16,311               23,956 
   Research and 
    development                      18,138                 14,345                 48,263               71,942 
   Cost of goods 
    sold                                  -                      -                      -                  760 
Total operating 
 expenses                            22,943                 19,546                 64,574               96,658 
                      ---------------------  ---------------------  ---------------------  ------------------- 
Loss from 
 operations                        (22,943)               (19,546)               (64,574)             (89,513) 
Other income 
(expense) 
   Gain on sale of 
    business                              -                  (177)                      -               87,266 
   Foreign exchange 
    loss                                (3)                      -                    (9)                  (3) 
   Other income                           -                    127                      -                  285 
   Interest income                    1,737                  1,850                  4,540                4,620 
                      ---------------------  ---------------------  ---------------------  ------------------- 
Total other income 
 (expense), net                       1,734                  1,800                  4,531               92,168 
                      ---------------------  ---------------------  ---------------------  ------------------- 
(Loss) income 
 before income tax 
 expense                           (21,209)               (17,746)               (60,043)                2,655 
   Income tax 
   expense 
   (benefit)                              -                      -                      -                    - 
                      ---------------------  ---------------------  ---------------------  ------------------- 
Net (loss) income          $       (21,209)       $       (17,746)       $       (60,043)    $           2,655 
                      =====================  =====================  =====================  =================== 
 
Net (loss) income 
per share: 
   Basic                $            (0.23)    $            (0.26)    $            (0.73)  $              0.04 
                      =====================  =====================  =====================  =================== 
   Diluted              $            (0.23)    $            (0.26)    $            (0.73)  $              0.04 
                      =====================  =====================  =====================  =================== 
 
Weighted average 
number of common 
shares outstanding 
   Basic                         93,866,642             69,204,899             82,086,813           59,417,911 
                      =====================  =====================  =====================  =================== 
   Diluted                       93,866,642             69,204,899             82,086,813           60,057,872 
                      =====================  =====================  =====================  =================== 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights-302932756.html

SOURCE Whitehawk Therapeutics, Inc.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment